EMEA-001940-PIP01-16-M02

Key facts

Invented name
Dovato
Active substance
  • lamivudine
  • dolutegravir
Therapeutic area
Infectious diseases
Decision number
P/0319/2019
PIP number
EMEA-001940-PIP01-16-M02
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
ViiV Healthcare UK Limited

E-mail: eu.paediatric-plans@gsk.com
Tel.: +44 (0)2089903650

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating